Pattern of Tissue Expression of CA-125 and HE4 in Primary Epithelial Ovarian Tumours and Correlation with Serum CA-125 Levels |
Devan, Shobana Mukunda
(Pathology Department, Faculty of Medicine, University of Malaya)
Pailoor, Jayalakshmi (Pathology Department, Faculty of Medicine, University of Malaya) Sthaneshwar, Pavai (Pathology Department, Faculty of Medicine, University of Malaya) Narayanan, Vallikkanu (Obstetrics and Gynaecology Department, Faculty of Medicine, University of Malaya) |
1 | Anastasi E, Marchei GG, Viggiani V, et al (2010). HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tum Biol, 31, 113-9. DOI ScienceOn |
2 | Bast RC Jr, Feeny M, Lazarus H, et al (1981). Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest, 68, 1331-7. DOI |
3 | Bast RC, Badgwell D, Lu Z, et al (2005). New tumor markers: CA125 and beyond. Int J Gynecol Cancer, 15, 274-81. DOI ScienceOn |
4 | Bergmann JF, Beaugrand M, Labadie H, et al (1986). CA 125 (ovarian tumour-associated antigen) in ascitic liver diseases. Clin Chim Acta, 155, 163-5. DOI ScienceOn |
5 | Breitenecker G, Neunteufel W, Bieglmayer C, et al (1989). Comparison between tissue and serum content of CA 125, CA 19-9 and carcinoembryonic antigen in ovarian tumours. Int J Gynecol Pathol, 8, 97-102. DOI |
6 | Chang X, Ye X, Cheng H, et al (2011). Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma. Int J Gynec Cancer, 5, 852-8. |
7 | Drapkin R, von Horsten HH, Lin Y, et al (2005). Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res, 65, 2162-9. DOI ScienceOn |
8 | Escudero JM, Auge JM, Filella X, et al (2011). Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin Chem, 57, 1534-44. DOI ScienceOn |
9 | Freydanck MK, Laubender RP, Rack B, et al (2012). Two-marker combinations for pre-operative discrimination of benign and malignant ovarian masses. Anticancer Res, 32, 2003-8. |
10 | Galgano MT, Hampton GM, Frierson HF Jr, et al (2006). Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol, 19, 847-53. |
11 | Goonewardene TI, Hall MR, Rustin GJ (2007). Management of symptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncol, 8, 813-21. DOI ScienceOn |
12 | Hala AA, Hany AL, Samar MS, et al (2010). HE4 and mesothelin: Novel biomarkers of ovarian carcinoma in patients with pelvic masses. Asian Pac J Cancer Prev, 11, 111-6. |
13 | Hellstrom I, Hellstrom KE (2008). SMRP and HE4 as Biomarkers for Ovarian Carcinoma When Used Alone and in Combination with CA125 and/or Each Other. Ovarian Cancer, 622, 15-21. DOI ScienceOn |
14 | Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al (2003). The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res, 63, 3695-700. |
15 | Hogdall EV, Christensen L, Kjaer SK, et al (2007). CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish “MALOVA” Ovarian Cancer Study. Gynecol Oncol, 104, 508-15. DOI ScienceOn |
16 | Holcomb K, Vucetic Z, Miller MC, et al (2011). Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women. Am J Obstet Gynecol, 205, 1-6. DOI ScienceOn |
17 | Huhtinen K, Suvitie P, Hiissa J, et al (2009). Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer, 100, 1315-9. DOI ScienceOn |
18 | Kim YM, Whang DH, Park J, et al (2011). Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA 125 for detecting ovarian cancer: a prospective case-control study in a Korean population. Clin Chem Lab Med, 49, 527-34. |
19 | Kirchoff C, Habben I, Ivell R, et al (1991). A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod, 45, 350-7. DOI |
20 | Kobel M, Kalloger SE, Carrick J, et al (2009). A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol, 33, 14-21. DOI ScienceOn |
21 | Madore J, Ren F, Filali-Mouhim A, et al (2010). Characterisation of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. J Pathol, 220, 392-400. |
22 | Kondalsamy-Chennakesavan S, Hacketal A, Bowtell D, et al (2013). Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient’s age. Gynecol Oncol, 129, 467-71. DOI ScienceOn |
23 | Lenhard M, Stieber P, Hertlein L, et al (2011). The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses. Clin Chem Lab Med, 49, 2081-8. |
24 | Lim GCC, Rampal S, Halimah Y (2008). Cancer incidence in Peninsular Malaysia 2003-2005.The Third Report of the National Cancer Registry, National Cancer Registry, Ministry of Health Malaysia, Kuala Lumpur. |
25 | Markman M (1997). The role of CA-125 in the management of ovarian cancer. Oncologist, 2, 6-9. |
26 | Molina R, Escudero JM, Auge JM, et al (2011). HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biol, 32, 1087-95. DOI ScienceOn |
27 | Montagnana M, Danese E, Ruzzenente O, et al (2011). The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med, 49, 521-5. |
28 | Moore RG, McMeekin DS, Brown AK, et al (2009). A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol, 112, 40-6. DOI ScienceOn |
29 | Park YJ, Lee JH, Hong DJ, et al (2011). Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases. Clin Biochem, 44, 884-8. DOI ScienceOn |
30 | Paramasivam M, Tripcony I, Crandon A, et al (2005). Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithekial ovarian cancer: an Australian multicenter study. J Clin Oncol, 23, 5938-42. DOI ScienceOn |
31 | Rosen DG, Wang L, Atkinson JN, et al (2005). Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol, 99, 267-77. DOI ScienceOn |
32 | Ruggeri G, Bandiera E, Zanotti L, et al (2011). HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and algorithm. Clin Chim Acta, 412, 1447-53. DOI ScienceOn |
33 | Shah CA, Lowe KA, Paley P (2009). Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. Cancer Epidemiol Biomarkers Prev, 18, 1365-72. DOI ScienceOn |
34 | Strugeon CM, Duffy MJ, Stenman UH, et al (2008). National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for the use of tumour markers in testicular, prostatic, colorectal, breast and ovarian cancer. Clin Chem, 54, 11-79. DOI ScienceOn |
35 | Terry K, Sluss P, Skates S, et al (2004). Blood and urine markers for ovarian cancer: a comprehensive review. Dis Markers, 20, 53-70. DOI |
36 | Urban N, Thorpe J, Karlan BY, et al (2012). Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev, 12, 2087-94. |